Keywords: Biomarkers, Preclinical, Glutaminolysis, Mantle Cell Lymphoma Models, Early Metabolic Biomarker of Response, Proton MRS with Slice Selective Double Frequency Hadamard Selective Multiple Quantum Coherence Transfer Pulse Sequence
Motivation: Mantle cell lymphoma (MCL) poses clinical challenges due to resistance to current treatment modalities. Targeting cell metabolism may prove new therapeutic approach to MCL.
Goal(s): We evaluated effectiveness of CB-839, a glutaminase inhibitor, against MCL in in vitro and in vivo preclinical studies.
Approach: We employed 1H magnetic resonance spectroscopy (1H MRS) imaging and biochemical analyses to investigate the effects of CB-839 on key metabolites in MCL cells, to potentially identify biomarkers of treatment response.
Results: Decreases in lactate and alanine concentration emerged as promising biomarkers of response to CB-839 and may potentially serve as biomarkers in MCL patients.
Impact: Therapy-mediated decreased intra-tumoral concentrations of lactate and alanine measured by 1H MRS may potentially become early and sensitive biomarkers of glutaminase inhibition in MCL and, likely, other types of malignancies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords